Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common genetic cause of Parkinson's disease (PD). Unexpectedly, tau pathology has been reported in a subset of LRRK2 mutation carriers. Methods: To estimate the frequency of pathogenic LRRK2 mutations and to evaluate the association of common LRRK2 variants with risk of primary tauopathies, we studied 1039 progressive supranuclear palsy (PSP) and 145 corticobasal degeneration patients from the Mayo Clinic Florida brain bank and 1790 controls ascertained at Mayo Clinic. Sanger sequencing of LRRK2 exons 30, 31, 35, and 41 was performed in all patients, and genotyping of all 17 known exonic variants with minor allele frequency >0.5% was performed in patients and controls. Results: LRRK2 mutational screening identified 2 known pathogenic mutations (p.G2019S and p.R1441C), each in 1 PSP patient, the novel p.A1413T mutation in a PSP patient and the rare p.R1707K mutation in a corticobasal degeneration patient. Both p.A1413T and p.R1707K mutations were predicted damaging by at least 2 of 3 prediction programs and affect evolutionary conserved sites of LRRK2. Association analysis using common LRRK2 variants only showed nominal association of the p.L153L variant with PSP. Conclusions: Our study confirms the presence of pathogenic and potentially pathogenic LRRK2 mutations in pathologically confirmed primary tauopathies, albeit with low frequency. In contrast to PD, common LRRK2 variants do not appear to play a major role in determining PSP and corticobasal degeneration risk. V C 2016 International Parkinson and Movement Disorder Society.
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Key W ords: LRRK2; tauopathy; PSP; CBD; mutation Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are primary neurodegenerative tauopathies characterized by neuronal loss and gliosis associated with abnormal aggregation of hyperphosphorylated tau. A tau isoform that has 4 31 amino acid repeats in the microtubule-binding domain (4R tau) tends to preferentially accumulate within lesions of both PSP and CBD. Despite having overlapping features, PSP and CBD have distinctive neuropathological and biochemical profiles. In PSP, neurofibrillary tangles (NFT), neuropil threads (NTs), and tau-positive tufted astrocytes (TAs) are predominantly found in the basal ganglia and brain stem, whereas in CBD pretangles, NTs and astrocytic plaques are found in the gray and white matter of the cortex, basal ganglia, diencephalon, and rostral brain stem. 1 The classical clinical presentation of PSP is called PSP with Richardson's syndrome (PSP-RS) and consists of an akinetic-rigid syndrome, supranuclear gaze palsy, cognitive impairment, and falls. However, at least 8 additional clinical types have been reported. 2 CBD presents clinically with diverse motor, sensory, behavioral, and cognitive symptoms. 3 Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease (PD). Rare and common LRRK2 variants have been associated with both familial and sporadic PD with clear pathogenic evidence for at least 5 variants: p.R1441C, p.R1441G, p.Y1699C, p.G2019S, and p.I2020T. Although predominantly associated with Lewy body (LB) pathology and clinical typical parkinsonism, LRRK2 mutations can present with other non-PD manifestations including significant taupositive aggregates and NFT. 4 The search for LRRK2 mutations in other non-PD populations has resulted in the identification of mutations in clinical PSP 5 and corticobasal syndrome 6 but also in negative reports in clinical [7] [8] [9] and in pathology-confirmed PSP and CBD. [10] [11] [12] [13] Most studies, however, analyzed small patient cohorts and, with a few exceptions, they limited the analysis to a few known LRRK2 variants. In this study, we aimed to determine the frequency of known and novel pathogenic LRRK2 mutations in a large series of autopsy-confirmed PSP and CBD cases and to evaluate the association of common LRRK2 variants with the risk of both diseases.
Methods

Study Subjects
A total of 1039 PSP and 145 CBD autopsyconfirmed cases and 1790 clinical controls were included in this study. PSP and CBD brains were submitted to the Mayo Clinic brain bank for neurodegenerative disorders between 1998 and 2014. Neuropathologic diagnosis was rendered by a single neuropathologist (DWD) and followed published criteria for PSP 14 and CBD. 15 Neuropathology studies included immunohistochemistry for phospho-tau and semiquantitative analysis of neuronal and glial tau pathology in 20 brain regions of each case, thioflavin-S fluorescent microscopy, and the measurement of the Braak NFT stage and Thal amyloid phase. 16 Clinical and demographic information was collected from available medical records. Summary of the characteristics of the PSP, CBD, and control populations are displayed in Supplementary Table 1 . Controls were neurologically normal volunteers evaluated in neurology clinics at Mayo Clinic in Jacksonville, Florida. Study subjects were recruited through protocols approved by the Mayo Clinic institutional review board.
Genetic Analysis
Genomic DNA was extracted from brain tissue in PSP and CBD cases and from peripheral blood in the control population. For the mutational screening, LRRK2 exons 30, 31, 35, and 41 and flanking intronic sequences were sequenced bidirectionally in all cases as previously described. 17 The DNA mutation annotation was based on the LRRK2 cDNA sequence of NM_198578.3. Phylogenetic and molecular evolutionary analyses were conducted using MEGA 7.09 running the MUSCLE program (http://www.megasoftware.net/). For common variant association, all 17 LRRK2 exonic variants that were previously observed with a minor allele frequency of 0.5% or greater by the M1646T, and p.S1647T) and 37 (p.G1819G). The rs76904798 variant that was recently identified as a risk factor for PD in a large meta-analysis of a genome-wide association study 19 was genotyped by TaqMan genotyping assay. All genotype call rates were >99%, and there was no evidence of a departure from the Hardy-Weinberg equilibrium in the controls for any variant (all P > .05). Linkage-disequilibrium between variants in controls is shown Supplementary  Tables 2a and 2b .
Statistical Analysis
The associations of each common LRRK2 variant with risk of PSP and CBD were assessed (ie, each disease separately vs controls) using logistic regression models adjusting for age (age at death in PSP and CBD patients and age at last follow-up in controls) and gender. Definite and potentially pathogenic LRRK2 mutation carriers, related individuals, and patients with an ethnicity different than white were excluded from this analysis; this resulted in a total of 998 PSP and 135 CBD autopsy-confirmed cases (Supplementary Table 1 ). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated, and each LRRK2 variant was examined under a dominant model (ie, presence vs absence of the minor allele) as a result of the small number of homozygotes of the minor allele for many of the variants. The association of the p.N551K-R1398H-K1423K haplotype with risk of PSP and CBD was evaluated using a logistic regression framework with adjustments for age and gender; ORs and 95% CIs were obtained in comparison to the common C-G-G haplotype. 20 The associations of a haplotype involving all 18 LRRK2 variants with a risk of PSP and CBD were examined using score tests for the association with adjustments for age and gender. 21 Haplotypes occurring in less than 1% of subjects were excluded from all haplotype analysis. To adjust for multiple testing in single-variant analysis, we used a single-step minP permutation correction separately when evaluating associations of LRRK2 variants with PSP and CBD; after this adjustment, P values .0036 (PSP vs controls) and .0038 (CBD vs controls) were considered as statistically significant. All statistical analyses were performed using R Statistical Software version 3.0.2 (https://www.r-project.org/).
Results
LRRK2 Mutation Screening
Sequencing of LRRK2 exons 30, 31, 35, and 41 in our PSP and CBD cases resulted in the identification of 4 definite or potentially pathogenic mutations. Of the PSP cases, 3 were identified carrying LRRK2 mutations: 1 p.G2019S, 1 novel p.A1413T, and 1 p.R1441C mutation. The latter individual is the proband of Family D that has been previously reported. 22 The p.A1413T mutation was identified in a Hispanic PSP patient and results from a c.4237 G>A heterozygous change in exon 30. This mutation has not been reported before in the Database of short Genetic Variations (dbSNP), Exome Variant Server (EVS) database (http://evs.gs.washington.edu/EVS/ April 2016) or Exome Aggregation Consortium (ExAC) (http://exac. broadinstitute.org April 2016), which includes exome data of 5,789 individuals from a Latino population. This variant was predicted to be "disease causing" by Mutation Taster (http://www.mutationtaster.org/) and "possibly damaging" by Polyphen-2 (http://genetics. bwh.harvard.edu/pph2/) programs and is located in a conserved site that is part of the LRRK2 Roc domain (Fig. 1A,B) .
FIG. 1.
LRRK2 functional domains and localization of known PD pathogenic mutations (top), mutations presenting as PSP (red) and the p.R1707K mutation found in a corticobasal degeneration patient (green) (A). Conservation analysis of leucine-rich repeat kinase 2 gene p.A1413T (B) and p.R1707K mutations (C).
In the CBD cohort, 1 case was found to carry a heterozygous c.5120 G>A change in exon 35 that results in a p.R1707K change (Fig. 1A ). This variant is reported in dbSNP (rs200769426) as identified by LRRK2 deep sequencing in 1 individual from a total of 14,002 participants. 23 The carrier of this variant is a 19-year-old woman affected with irritable bowel disease-constipation (IBS) who is a native from England (L. McCarthy, GlaxoSmithKline (GSK), personal communication). This variant is predicted to be "damaging" with SIFT (http://sift.jcvi.org/), Mutation Taster and Polyphen-2 programs and is located in an evolutionarily conserved site in the LRRK2 C-terminal of ROC (COR) domain (Fig. 1C) .
We also genotyped LRRK2 p.R1628P (rs33949390) because although this variant is observed rarely in whites, 18 it has been shown to be a PD risk factor in Asian populations. 24 The p.R1628P variant was not observed in controls, but was seen in 2 PSP cases (0.2% of patients) and 1 CBD case (0.7% of patients), all of them of white ethnicity.
LRRK2 Common SNP Association
An evaluation of the associations of common LRRK2 variants with a risk of PSP and CBD is provided in Table 1 . Although the size of our PSP cohort provided enough statistical power to detect significant associations, no LRRK2 variants were found associated with a risk of PSP after adjustment for multiple testing; however, there was a nominally significant association with the p.L153L variant (OR 1.22, 95% CI 1.04-1.44, P 5 .014). A similar nonsignificant trend was noted for CBD (OR 1.42, 95% CI 0.97-2.08, P 5 .065), but we were underpowered to detect associations in this cohort because of its size. There were no other nominal associations with a risk of PSP or CBD for any of the other LRRK2 variants that were examined (all Ps .10). Of particular interest, the p.M1646T PD risk factor was not associated with PSP (OR 1.03, 95% CI 0.63-1.68, P 5 .90) or CBD (OR 1.12, 95% CI 0.39-3.19, P 5 .84). A detailed summary of allele and genotype frequencies for common variants is provided in Supplementary Tables 3a-3c .
The p.N551K-R1398H-K1423K haplotype that is protective for PD 18, 25 was not found to be associated with a risk of PSP (OR 0.99, 95% CI 0.80-1.23, P 5 .92) or CBD (OR 1.16, 95% CI 0.73-1.85, P 5 .52). When examining a general haplotype that included all 18 common LRRK2 variants, there was no association with PSP (P 5 .69); however, there was a significant association with CBD (P 5 .011). As displayed in Table 2 , there was 1 haplotype (haplotype 1) that was less common in CBD patients than controls (3.2% vs 6.0%, P 5 .024), and 2 haplotypes (haplotypes 17 and 18) that were more common in CBD patients when compared with controls (haplotype 17: 2.3% vs 1.1%, P 5 .033; haplotype 18: 4.0% vs 1.8%, P 5 .016). ORs, 95% CIs, and P values result from logistic regression models adjusted for age (age at death in PSP/CBD patients, age at last follow-up in controls) and gender. LRRK2 variants were examined under a dominant model; ORs correspond to presence of the minor allele. After applying a single-step minP permutation adjustment for multiple testing, P values 0.0036 (PSP vs controls) and 0.0038 (CBD vs controls) were considered as statistically significant. CBD, corticobasal degeneration; MA, minor allele; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.
S A N C H E Z -C O N T R E R A S E T A L
Clinicopathological Characteristics of the LRRK2 p.G2019S PSP Carrier
This patient (patient 4 in Supplementary Tables 4a-c) was an 80-year-old white Jewish woman who presented with progressive gait difficulties and falls at the age of 73. In the early stage of the disease, the patient developed dysarthria, dysphagia, intermittent left hand tremor, vertical gaze palsy, and retrocollis. The patient became wheelchair bound and was found to have pseudobulbar palsy and mild memory impairment 3 years later (27/30 on the Mini-Mental State Examination [MMSE] ). There was hand-as-object apraxia on the left, bradydiadochokinesia, spasticity, and ataxia of her upper limbs. Under the suspicion of probable PSP, the PSP Rating scale was conducted and the patient scored 51/100. Her Frontal Assessment Battery score was 13/18. MRI showed mild generalized atrophy. On autopsy, her brain weight was 1080 grams. There was mild atrophy over the frontal convexity with mild enlargement of the frontal horn of the lateral ventricle (Fig. 2A) . The subthalamic nucleus (STN) was slightly atrophic and the cerebellar hilus, substantia nigra (SN), and the locus coeruleus were remarkable for decreased pigmentation. Microscopically, there was moderate neuronal loss and gliosis with NFT, coiled bodies, and TAs in the STN. The globus pallidus (GP) had mild gliosis. There was myelinated fiber loss and gliosis in the superior cerebellar peduncle, and the dentate nucleus (DN) was mildly atrophic with severe neuronal loss and grumose degeneration. There was moderate neuronal loss and gliosis with globose NFT, but no LBs in the SN. The raphe nuclei, locus ceruleus, pontine, and medullary reticular formation had many pretangles and threads. On thioflavin-S staining, many senile plaques (SP) and sparse NFT were detected. The neuropathologic diagnosis was PSP with early stage AD.
Clinicopathological Characteristics of the LRRK2 p.A1413T PSP Carrier
This patient (patient 5 in Supplementary Tables 4a-c) was a 79-year-old Filipino man who presented at the age of 72 years with progressing memory problems and gait difficulties with severe postural instability and falls as well as apraxia of eyelid opening. On neurological examination 1 year before his death, the patient showed rigidity of his limbs and axial rigidity with retrocollis, vertical supranuclear palsy, hypomimia, spastic dysarthria, severe bradykinesia, but no tremor. The patient was wheelchair bound and had urinary incontinency. MRI revealed brain stem atrophy. Trials of levodopa (up to 600 mg/d), donepezil, onabotulinumtoxinA, quetiapine, and risperidone had no durable benefit. On autopsy, his brain weighed 1100 g. There was a mild atrophy over the frontal convexity, remarkable STN, and SN atrophy (Fig. 2B ). There were also decreased pigmentation of the SN and locus coeruleus and mild atrophy of the DN with minimal discoloration of the P values result from score tests for association. CBD, corticobasal degeneration; LRRK2, leucine-rich repeat kinase 2 gene.
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Movement Disorders, Vol. 32, No. 1, 2017 cerebellar hilus. There was extensive neuronal and glial pathology, including pretangles, NTs, flame-shaped and globoid NFT, TAs (Fig. 2C) , grains (Fig. 2D) , coiled bodies, and a few ballooned neurons; thus, the clinical diagnosis of PSP could be confirmed by the neuropathology examination. The SN showed moderate to marked neuronal loss with globose NFT, but no LBs (Fig. 2E-F) . The basal ganglia had no SP, but NFT and TAs. The GP had gliosis, and the STN had mild neuronal loss, marked gliosis, and many NFT (Fig. 2G-H) . On thioflavin-S staining, no SP and only rare NFT were noted.
Clinicopathological Characteristics of the LRRK2 p.R1707K CBD Carrier
This patient was an 84-year-old right-handed woman with a 6-year history of progressive cognitive decline. MMSE showed a 4-point decline in scores per year, reaching 18/30 when last tested 4 years before she died. Around that time, a clinical examination revealed apathy. Except for Babinski's sign on the left, no further neurological abnormalities were recorded. Her family history was negative for neurodegenerative disorders, but notable for stroke in her sister. The patient's tentative diagnosis was mixed multiinfarct and AD-type dementia. On autopsy, her brain weighed 1000 grams and showed diffuse cortical atrophy, most prominent in the superior frontal gyrus with marked enlargement of the frontal horn of the lateral ventricles (Fig. 3A, asterisk) . There was mild atrophy of the anterior corpus callosum, amygdala, hippocampus, and midbrain, but the basal ganglia, thalamus, and STN were unremarkable. The SN showed marked depigmentation, and there was no atrophy of the superior cerebellar peduncle and no atrophy or discoloration of the DN. Tau immunohistochemistry showed many cortical pretangles and threads in gray and white matter as well as numerous astrocytic plaques (Fig. 3B) . There was thinning of the cortical ribbon with spongiosis, gliosis, and ballooned neurons particularly in parietal, limbic, and superior frontal cortices (Fig. 3C,D) . The hippocampus and amygdala had no significant neuronal loss but many pretangles and threads. Ballooned neurons were present in the amygdala. The basal ganglia had many pretangles, threads, and astrocytic plaques in the corpus stratum. The SN had marked neuronal loss with NFT ("corticobasal bodies") (Fig. 3E,F) . There was much less severe tau pathology in the lower brain stem, and it was nearly completely absent in the cerebellum. 
S A N C H E Z -C O N T R E R A S E T A L
NFT and amyloid deposition on Thioflavin-S staining corresponded with Braak NFT stage II and Thal amyloid phase 3. The findings were compatible with CBD with additional AD-type pathology.
Discussion
Mutations in LRRK2 are a common genetic factor for both familial and sporadic PD, but studies have suggested that LRRK2 mutations may also be involved in PSP and related tauopathies such as CBD. In this study, we performed a systematic genetic analysis of LRRK2 mutations and genetic association studies in the largest cohort of autopsy-confirmed PSP and CBD studied to date. In line with earlier reports, we identified 3 LRRK2 mutations in PSP patients, and we also reported the first CBD case with a likely pathogenic LRRK2 mutation. Therefore, although these mutation frequencies are low, our findings do confirm that LRRK2 mutations can lead to the development of primary tauopathies and emphasize that LRRK2 should be considered the second most common causal gene for this group of diseases after the microtubule associated protein tau (MAPT). Moreover, because our study only focused on LRRK2 coding exons in which pathogenic mutations had previously been reported, we cannot rule out the presence of additional mutations in other LRRK2 regions.
We have previously defined 2 main types of clinicopathological presentations in LRRK2 mutation carriers: the most common defined as the typical PD type, and a second type presenting with "pure nigral degeneration" with no LB pathology. 26 A third type of clinicopathological manifestation of LRRK2 mutations has been suggested by Spanaki and colleagues 27 to classify a transitional form between PD and PSP observed in a carrier of the p.R1441H mutation, and the p.R1441C mutation carrier from family D (this patient correspond to the mutation carrier reported in this study and to patient 1 in Supplementary Tables 4a-c) . 22 Later on, Ruffmann and colleagues 28 further defined this third type of LRRK2 mutation carrier by describing the similarities between the p.R1441C mutation carrier from family D and 2 additional p.G2019S carriers (patients 2 and 3 in Supplementary Tables 4a-c), manifesting with PSP-like 4R tauopathy pathology with mainly subcortical involvement. The parkinsonian presentation and milder severity of PSP pathology in these 3 cases are consistent with their classification as PSP-P. 29 Moreover, the suspected specificity of LRRK2 mutations for PSP-P may explain the failure to detect LRRK2 mutations in clinical PSP cohorts, which would be mostly patients with PSP-RS. 9 Because to date these 3 cases were the only LRRK2 mutation carriers presenting with PSP pathology described in the literature, we performed a comparison between them and our 2 PSP mutation carriers newly identified in this study (patients 4 and 5 in Supplementary Tables 4a-c) . The medical records of our 2 cases support the fact that they had a typical PSP-RS clinical presentation that contrasts with the absence of classical PSP symptoms in the 3 previously reported cases. However, given that the medical history is recorded retrospectively in our cases, we cannot exclude that they presented a 
parkinsonian syndrome early in the course of their disease. Similar to the cases described by Ruffmann and colleagues, our 2 PSP cases also had predominant subcortical tauopathy and no LB pathology, but a detailed observation of the tauopathy severity indicates that our 2 cases had a more severe presentation when compared with the 3 previous cases and fulfilled all neuropathological criteria for PSP. We also identified a LRRK2 p.R1707K mutation in a patient with autopsy-confirmed CBD. The clinical presentation was of progressive cognitive impairment with apraxia and language difficulties, but no other features to meet clinical criteria for CBD. 3 The only major differential diagnosis would have been frontotemporal dementia and parkinsonism linked to chromosome 17, 15 but this was excluded by genetic studies. To our knowledge, LRRK2 p.R1707K is the first mutation other than MAPT mutations 30 to be reported in autopsy-confirmed CBD. In support of its pathogenicity, the p.R1707K has not been observed in controls, is predicted to be damaging to the LRRK2 protein, and is at an evolutionarily conserved site. In addition, the p.R1707K is located near the pathogenic p.Y1699C mutation, and both mutations are located in the LRRK2 COR domain (Fig. 1A) . However, different from the p.R1707K mutation, the p.Y1699C mutation has been associated with clinical PD, SN degeneration, and the absence of tauopathy. 22 The p.R1707K mutation has been reported in the dbSNP database and, interestingly, this mutation carrier is affected with IBS. The fact that genome-wide association studies have also linked LRRK2 variants to Crohn's disease, a form of IBS, supports the pleomorphic nature of LRRK2 mutations.
Finally, using common variant association analyses, we show that individual common LRRK2 variants that have previously been associated with risk of PD (p.M1646T and the p.N551K-R1398H-K1423K haplotype) are not associated with PSP or CBD. Interestingly, we did observe a nominally significant association between p.L153L and risk of PSP (P 5 .014), with a similar but nonsignificant association for CBD (P 5 .065). Because these associations were not significant after an adjustment for multiple testing, it will be important to further assess them in additional, independent PSP and CBD cohorts. We also detected a significant association between a haplotype involving all 18 common LRRK2 variants and risk of CBD, but given that the specific haplotypes that appeared to differ between CBD patients and controls were all rare, an examination of this finding in a larger series will also be needed. Importantly, the possibility of type II error (ie, a false-negative association) also cannot be excluded, and emphasis should be placed on 95% confidence limits when interpreting our results, especially in the smaller CBD series where association ORs are less precise.
In conclusion, our study emphasizes the importance of LRRK2 as a rare causative gene in pathologically confirmed PSP and CBD. More phenotype-genotype correlative studies and association studies in larger cohorts are now needed to elucidate how LRRK2 mutations result in different clinical and pathological manifestations and to clarify a possible link between LRRK2 variation and tau hyperphosphorylation and aggregation.
